DE69232986D1 - TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG - Google Patents

TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG

Info

Publication number
DE69232986D1
DE69232986D1 DE69232986T DE69232986T DE69232986D1 DE 69232986 D1 DE69232986 D1 DE 69232986D1 DE 69232986 T DE69232986 T DE 69232986T DE 69232986 T DE69232986 T DE 69232986T DE 69232986 D1 DE69232986 D1 DE 69232986D1
Authority
DE
Germany
Prior art keywords
cdns
tgf
coding
type iii
beta type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232986T
Other languages
English (en)
Other versions
DE69232986T2 (de
Inventor
Y Lin
Xiao-Fan Wang
A Weinberg
F Lodish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25137484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232986(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of DE69232986D1 publication Critical patent/DE69232986D1/de
Application granted granted Critical
Publication of DE69232986T2 publication Critical patent/DE69232986T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE69232986T 1991-10-31 1992-10-30 TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG Expired - Lifetime DE69232986T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78606391A 1991-10-31 1991-10-31
PCT/US1992/009326 WO1993009228A1 (en) 1991-10-31 1992-10-30 TGF-β TYPE RECEPTOR cDNAS AND USES THEREFOR

Publications (2)

Publication Number Publication Date
DE69232986D1 true DE69232986D1 (de) 2003-05-08
DE69232986T2 DE69232986T2 (de) 2003-12-11

Family

ID=25137484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232986T Expired - Lifetime DE69232986T2 (de) 1991-10-31 1992-10-30 TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG

Country Status (9)

Country Link
US (7) US6010872A (de)
EP (2) EP0610427B1 (de)
JP (2) JP4124815B2 (de)
AU (1) AU671606B2 (de)
CA (1) CA2122491A1 (de)
DE (1) DE69232986T2 (de)
ES (1) ES2191007T3 (de)
HK (1) HK1040744A1 (de)
WO (1) WO1993009228A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134656A (en) * 1992-09-03 2006-12-10 Univ California Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies
EP0669833B1 (de) * 1992-10-29 2002-06-12 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
AU7605394A (en) * 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
BRPI0307070A2 (pt) * 2002-01-22 2019-03-26 Genzyme Corporation uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US8058077B2 (en) * 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
JP4543189B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ＴＧＦβ１レセプターＩＩ型に対するＲＮＡｉとして作用するＲＮＡ配列
AU2005230848B9 (en) * 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
JP4706193B2 (ja) * 2004-05-27 2011-06-22 国立大学法人 長崎大学 マルファン症候群の分析のためのプローブの使用、スクリーニング方法およびキット
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
JP2007043918A (ja) * 2005-08-08 2007-02-22 Medeinetto:Kk 腫瘍成長因子β受容体発現細胞株
JP5602365B2 (ja) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
JP2011045339A (ja) * 2009-08-28 2011-03-10 Univ Of Tokyo ＴＧＦ−βＩＩ型受容体に結合する核酸およびその使用
EP2544541B1 (de) 2010-03-12 2014-10-08 Genzyme Corporation Kombinationstherapie zur behandlung von brustkrebs
EP2660314A4 (de) 2010-12-27 2014-09-03 Lsip Llc Ips-zellen und verfahren zu ihrer erzeugung
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (de) 2011-10-26 2015-05-15 Seattle Childrens Res Inst
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
ES2845215T3 (es) 2013-03-11 2021-07-26 Genzyme Corp Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
EP3036262A4 (de) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Varianten von tgf-beta-rezeptortyp ii und verwendungen davon
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
JP7320350B2 (ja) 2015-08-04 2023-08-03 アクセルロン ファーマ インコーポレイテッド 骨髄増殖性障害を処置するための方法
EP3628049B1 (de) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Fusionsproteine vom tgf-beta-rezeptor typ ii und verwendungen davon
MX2019013023A (es) 2017-05-12 2019-12-18 Jiangsu Hengrui Medicine Co Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
MX2020013977A (es) 2018-06-22 2021-06-15 Kite Pharma Inc Proteínas quiméricas transmembrana y usos de las mismas.
WO2020094122A1 (zh) 2018-11-09 2020-05-14 江苏恒瑞医药股份有限公司 一种TGF-β受体融合蛋白药物组合物及其用途
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2023534738A (ja) 2020-07-24 2023-08-10 ▲邁▼威（上海）生物科技股▲フン▼有限公司 ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
EP0669833B1 (de) * 1992-10-29 2002-06-12 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel

Also Published As

Publication number Publication date
JP4124815B2 (ja) 2008-07-23
EP0610427A1 (de) 1994-08-17
US20060247198A1 (en) 2006-11-02
US6010872A (en) 2000-01-04
ES2191007T3 (es) 2003-09-01
WO1993009228A1 (en) 1993-05-13
US20080234216A1 (en) 2008-09-25
EP1149908A1 (de) 2001-10-31
JPH07501212A (ja) 1995-02-09
EP0610427B1 (de) 2003-04-02
HK1040744A1 (zh) 2002-06-21
AU671606B2 (en) 1996-09-05
DE69232986T2 (de) 2003-12-11
JP2006055164A (ja) 2006-03-02
US6046157A (en) 2000-04-04
US6201108B1 (en) 2001-03-13
CA2122491A1 (en) 1993-05-13
AU3057892A (en) 1993-06-07
US6086867A (en) 2000-07-11
US20050260579A1 (en) 2005-11-24
JP4185512B2 (ja) 2008-11-26

Similar Documents

Publication Publication Date Title
DE69232986T2 (de) TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
ATE199893T1 (de) Stilbenverbindungen mit adamantylgruppe, diese enthaltende zusammensetzungen und deren verwendung
DE59104033D1 (de) Intumeszenzträger und deren Verwendung.
DE69015886T2 (de) Fotochromische Verbindung, deren Zusammensetzung und Verwendung.
IT1313625B1 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
MX9201050A (es) Etiquita protegida, doblada y sellada, para la impresion requerida.
DE69915693D1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
DE69928140D1 (de) Antipicornavirale Verbindungen, deren Herstellung und Verwendung
DE69434698D1 (de) Verkehr mit konstanter bitrate in schnellen paketnetzen
DE69623698T2 (de) Druckapparat und diesen verwendenden Faksimileapparat
DE59008501D1 (de) Neue, stickstoffhaltige Titanocene und deren Verwendung.
DE69108218D1 (de) Kationische Copolymere, Emulsionen und deren Verwendung.
DE59203719D1 (de) Polymere Farbstoffe und deren Verwendung.
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE59300501D1 (de) Verbesserte Intumeszenzträger und deren Verwendung.
DE69202541D1 (de) Fahrzeugsitzleitschiene mit Festpunktrückführung.
DE58902272D1 (de) Substituierte naphthacen-5,12-dione und deren verwendung.
DE69109052D1 (de) Polyolefin-Zusammensetzung und deren Verwendung.
DE59400001D1 (de) Alkenylgruppen aufweisende Siloxancopolymere, deren Herstellung und Verwendung.
DE69432680D1 (de) Druckkopf-Substrat, Druckkopf mit Benützung desselben und Druckvorrichtung
TR28830A (tr) Insektisid özellikte N'-sübstitüe edilmis N,N`- diacilhidrazinler.
ATE90510T1 (de) Antimikrobische zusammensetzung und deren verwendung.
DE69323384D1 (de) Faksimilesystem mit schnurlosen Untereinheiten
DE69735123D1 (de) Trehalose phosphorylase, deren Herstellung und Verwendung
DE58907546D1 (de) Substituierte Naphthacen-5,12-dione und deren Verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition